To date, more than 10 different BsAbs-targeting MM antigens have been clinically investigated, most of them directed to BCMA and CD3 with promising clinical data from phase 1/2 studies (Table 2) [45]. Here, TNFRSF17 is linked to Miyoshi myopathy.